Gilead Sciences (GILD) Net Income towards Common Stockholders Growth (1y) (2010 - 2026)
Powered by 
Analysis
Gilead Sciences (GILD) Net Income towards Common Stockholders Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 65.85% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -635.24% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 6.48% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | -6.81% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 5.21% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 92.37% |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 327.74% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -84.64% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Insmed | 26.19 Bn | 25.03 Bn | 358.27 Mn | 95.87% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -635.24% |
| Mar 31, 2026 | 53.69% |
| Dec 31, 2025 | 41.86% |
| Sep 30, 2025 | 143.58% |
| Jun 30, 2025 | 21.42% |
| Mar 31, 2025 | 131.53% |
| Dec 31, 2024 | 25.85% |
| Sep 30, 2024 | -42.31% |
| Jun 30, 2024 | 55.44% |
| Mar 31, 2024 | -523.88% |
| Dec 31, 2023 | -13.29% |
| Sep 30, 2023 | 21.61% |
| Jun 30, 2023 | -8.46% |
| Mar 31, 2023 | 8,100.00% |
| Dec 31, 2022 | 334.31% |
| Sep 30, 2022 | -30.94% |
| Jun 30, 2022 | -25.18% |
| Mar 31, 2022 | -99.30% |
| Dec 31, 2021 | -75.65% |
| Sep 30, 2021 | 632.58% |